|
Clinical Scenario #1: Applying Biomarkers in Risk Stratification of Localized Prostate Cancer |
0.75 |
06/15/2023 - 12:00am to 06/15/2024 - 12:00am |
|
Management of Toxicities of BTK Inhibitors in B-Cell Malignancies |
0.75 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
|
Clinical Scenario #2: Applying Biomarkers in Breast Cancer |
0.75 |
06/15/2023 - 12:00am to 06/15/2024 - 12:00am |
|
Clinical Scenario #3: Applying Biomarkers in Central Nervous System Cancers |
0.75 |
06/15/2023 - 12:00am to 06/15/2024 - 12:00am |
|
Chronic Myeloid Leukemia/Myelofibrosis: TKI Therapy and Toxicity Management |
0.75 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
|
Clinical Scenario #4: Applying Biomarkers in Non-Small Cell Lung Cancer |
0.75 |
06/15/2023 - 12:00am to 06/15/2024 - 12:00am |
|
Clinical Scenario #5: Applying Biomarkers in Biliary Tract Cancers |
0.75 |
06/15/2023 - 12:00am to 06/15/2024 - 12:00am |
|
Prophylactic Vaccines/Immunizations for Cancer Patients |
0.75 |
08/04/2022 - 12:00am to 08/04/2024 - 12:00am |
|
Case Studies in the Management of Leukemia |
0.75 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
|
Psychotherapeutic Strategies and Pharmacotherapy Options for Addressing Distress in Cancer Patients |
0.75 |
08/04/2022 - 12:00am to 08/04/2024 - 12:00am |
|
Evaluating Immune Checkpoint Inhibition Response Biomarkers |
0.75 |
06/15/2023 - 12:00am to 06/15/2024 - 12:00am |
|
NCCN Guidelines® Insights - Survivorship, Version 1.2023 |
1.00 |
08/10/2023 - 12:00am to 08/10/2024 - 12:00am |
|
Recorded Presentation from the NCCN Pharmacy Updates: Ampullary Adenocarcinoma: Overview of Subtypes and Treatments |
1.00 |
09/21/2023 - 12:00am to 09/13/2024 - 12:00am |
|
Monthly Oncology Tumor Boards: Updates in Treatment of Hairy Cell Leukemia |
1.00 |
03/19/2024 - 12:00am to 08/04/2024 - 12:00am |
|
NCCN Guidelines® Insights - Breast Cancer Screening and Diagnosis, Version 1.2023 |
1.00 |
09/10/2023 - 12:00am to 09/10/2024 - 12:00am |
Facebook
Twitter
LinkedIn
Forward